{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:23:53Z","timestamp":1740144233954,"version":"3.37.3"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"20","license":[{"start":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T00:00:00Z","timestamp":1589500800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Primary central nervous system lymphoma (PCNSL) typically shows a strong uptake of <jats:sup>18<\/jats:sup>F-fludeoxyglucose (FDG) imaged by positron emission tomography (PET). Uncommonly, PCNSL demonstrates a low uptake on FDG PET. We investigated the clinicopathological characteristics of the unusual cases of PCNSL with low FDG uptake.<\/jats:p>\n            <jats:p>We retrospectively enrolled 104 consecutive patients with newly diagnosed PCNSL who underwent baseline brain FDG PET. The degree of FDG uptake of PCNSL was visually scored by 4 grades (0, \u2264contralateral white matter; 1, &gt;contralateral white matter and &lt;contralateral gray matter; 2, = contralateral gray matter; 3, &gt;contralateral gray matter). Grades 0\u20132 were considered as PCNSL with low uptake. We investigated association of low uptake of PCNSL with the following clinicopathological factors: age, sex, steroid treatment, lactate dehydrogenase level, cerebrospinal fluid protein level, condition of PET scanning, immunohistochemical markers (cluster of differentiation 10 [CD10], B-cell lymphoma 6 [BCL-6], B-cell lymphoma 2 [BCL-2], multiple myeloma oncogene 1 [MUM1], Epstein-Barr virus [EBV] protein, and Ki67), location of lesions, tumor size, multiplicity of lesions, involvement of deep brain structures, and cystic or necrotic appearance of lesions.<\/jats:p>\n            <jats:p>Of the 104 patients with PCNSL, 14 patients (13.5%) showed PCNSL with low FDG uptake on PET. Among various clinicopathological factors, MUM1 negativity was the only factor associated with low FDG uptake PCNSL by univariate (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.002) and multivariate analysis (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.007).<\/jats:p>\n            <jats:p>This study suggests that the different clinicopathological characteristics between patients with high uptake and low uptake of PCNSL on FDG PET is closely associated with lack of MUM1, a protein known to be a crucial regulator of B-cell development and tumorigenesis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000020140","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T15:57:00Z","timestamp":1589903820000},"page":"e20140","source":"Crossref","is-referenced-by-count":6,"title":["Clinicopathological characteristics of primary central nervous system lymphoma with low 18F-fludeoxyglucose uptake on brain positron emission tomography"],"prefix":"10.1097","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9983-7438","authenticated-orcid":false,"given":"Hye Ok","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, College of Medicine, Ewha Womans University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Seung","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9010-5460","authenticated-orcid":false,"given":"Seon-Ok","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Biostatistics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun Young","family":"Chae","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Jun","family":"Oh","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minjung","family":"Seo","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Ulsan University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4580-3918","authenticated-orcid":false,"given":"Suk Hyun","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine, Department of Radiology, Hallym University Kangnam Sacred Heart Hospital, Hallym University College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jungsu S.","family":"Oh","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8339-2809","authenticated-orcid":false,"given":"Jin-Sook","family":"Ryu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joo-ryung","family":"Huh","sequence":"additional","affiliation":[{"name":"Department of Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong Hoon","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,5,15]]},"reference":[{"key":"R1-20240521","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1158\/1078-0432.CCR-10-1161","article-title":"Primary CNS lymphoma in children and adolescents: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG)","volume":"17","author":"Abla","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R2-20240521","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1200\/JCO.2005.04.8819","article-title":"Primary CNS lymphoma","volume":"24","author":"Batchelor","year":"2006","journal-title":"J Clin Oncol"},{"key":"R3-20240521","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.lungcan.2012.11.021","article-title":"Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET\/CT","volume":"79","author":"Choi","year":"2013","journal-title":"Lung Cancer"},{"key":"R4-20240521","first-page":"3837","article-title":"Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography","volume":"6","author":"Vesselle","year":"2000","journal-title":"Clin Cancer Res"},{"key":"R5-20240521","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.2967\/jnumed.108.054098","article-title":"18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization","volume":"50","author":"Jadvar","year":"2009","journal-title":"J Nucl Med"},{"key":"R6-20240521","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s13139-013-0224-6","article-title":"18F-FDG PET in patients with primary systemic anaplastic large cell lymphoma: differential features according to expression of anaplastic lymphoma kinase","volume":"47","author":"Lee","year":"2013","journal-title":"Nucl Med Mol Imaging"},{"key":"R7-20240521","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/S0959-8049(02)00031-X","article-title":"Diagnostic advances and new trends for the treatment of primary central nervous system lymphoma","volume":"38","author":"Basso","year":"2002","journal-title":"Eur J Cancer"},{"key":"R8-20240521","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1023\/A:1006202402010","article-title":"Positron emission tomography in patients with primary CNS lymphomas","volume":"43","author":"Roelcke","year":"1999","journal-title":"J Neurooncol"},{"key":"R9-20240521","doi-asserted-by":"crossref","first-page":"W365","DOI":"10.2214\/AJR.07.2660","article-title":"18F-FDG PET of common enhancing malignant brain tumors","volume":"190","author":"Kosaka","year":"2008","journal-title":"AJR Am J Roentgenol"},{"key":"R10-20240521","first-page":"532","article-title":"Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography","volume":"33","author":"Rosenfeld","year":"1992","journal-title":"J Nucl Med"},{"key":"R11-20240521","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s00259-005-1917-6","article-title":"FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up","volume":"33","author":"Palmedo","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R12-20240521","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s12149-010-0356-z","article-title":"Use of PET in the diagnosis of primary CNS lymphoma in patients with atypical MR findings","volume":"24","author":"Kawai","year":"2010","journal-title":"Ann Nucl Med"},{"key":"R13-20240521","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"R14-20240521","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/PAI.0b013e3181cf1126","article-title":"MUM1\/IRF4: a review","volume":"18","author":"Gualco","year":"2010","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"R15-20240521","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3324\/haematol.10682","article-title":"MUM1 expression dichotomises follicular lymphoma into predominantly, MUM1-negative low-grade and MUM1-positive high-grade subtypes","volume":"92","author":"Naresh","year":"2007","journal-title":"Haematologica"},{"key":"R16-20240521","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1097\/PAS.0b013e3181bb9a18","article-title":"Nodal diffuse large B-cell lymphomas in children and adolescents: immunohistochemical expression patterns and c-MYC translocation in relation to clinical outcome","volume":"33","author":"Gualco","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"R17-20240521","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1158\/1078-0432.CCR-08-1845","article-title":"IRF4: immunity. Malignancy! Therapy?","volume":"15","author":"Shaffer","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R18-20240521","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/sj.leu.2401748","article-title":"MUM1: a step ahead toward the understanding of lymphoma histogenesis","volume":"14","author":"Gaidano","year":"2000","journal-title":"Leukemia"},{"key":"R19-20240521","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3960\/jslrt.53.141","article-title":"Double-hit lymphoma demonstrating t(6;14;18)(p25;q32;q21), suggesting two independent dual-hit translocations, MYC\/BCL-2 and IRF4\/BCL-2","volume":"53","author":"Tabata","year":"2013","journal-title":"J Clin Exp Hematop"},{"key":"R20-20240521","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1158\/1078-0432.CCR-12-0977","article-title":"c-Myc and cancer metabolism","volume":"18","author":"Miller","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R21-20240521","doi-asserted-by":"crossref","first-page":"5164","DOI":"10.1158\/0008-5472.CAN-10-4633","article-title":"18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers","volume":"71","author":"Palaskas","year":"2011","journal-title":"Cancer Res"},{"key":"R22-20240521","doi-asserted-by":"crossref","first-page":"6479","DOI":"10.1158\/1078-0432.CCR-09-0889","article-title":"MYC-induced cancer cell energy metabolism and therapeutic opportunities","volume":"15","author":"Dang","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R23-20240521","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1177\/1947601910378691","article-title":"MYC and breast cancer","volume":"1","author":"Xu","year":"2010","journal-title":"Genes Cancer"},{"key":"R24-20240521","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature07064","article-title":"IRF4 addiction in multiple myeloma","volume":"454","author":"Shaffer","year":"2008","journal-title":"Nature"},{"key":"R25-20240521","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1167\/iovs.05-0318","article-title":"Expression of immunoglobulin transcription factors in primary intraocular lymphoma and primary central nervous system lymphoma","volume":"46","author":"Coupland","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R26-20240521","first-page":"879","article-title":"Dexamethasone treatment and plasma glucose levels: relevance for fluorine-18-fluorodeoxyglucose uptake measurements in gliomas","volume":"39","author":"Roelcke","year":"1998","journal-title":"J Nucl Med"},{"key":"R27-20240521","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s002590050487","article-title":"Can the standardized uptake value characterize primary brain tumors on FDG-PET?","volume":"26","author":"Hustinx","year":"1999","journal-title":"Eur J Nucl Med"},{"key":"R28-20240521","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/leu.2011.169","article-title":"Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma","volume":"25","author":"Deckert","year":"2011","journal-title":"Leukemia"},{"key":"R29-20240521","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s11060-010-0182-0","article-title":"Prognostic value of pretreatment 18F-FDG PET in patients with primary central nervous system lymphoma: SUV-based assessment","volume":"100","author":"Kawai","year":"2010","journal-title":"J Neurooncol"},{"key":"R30-20240521","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2967\/jnumed.112.108654","article-title":"18F-FDG PET is an independent outcome predictor in primary central nervous system lymphoma","volume":"54","author":"Kasenda","year":"2013","journal-title":"J Nucl Med"},{"key":"R31-20240521","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/1758834010365330","article-title":"Chemotherapy in newly diagnosed primary central nervous system lymphoma","volume":"2","author":"Hashemi-Sadraei","year":"2010","journal-title":"Ther Adv Med Oncol"},{"key":"R32-20240521","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020140","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T20:06:28Z","timestamp":1716321988000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,15]]},"references-count":32,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000020140","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2020,5,15]]}}}